NFKB1 and rheumatoid arthritis: The results obtained in the present study revealed the capability of both the A2AAR agonist CGS 21680 and the A3AR agonist Cl-IB-MECA to reduce NF-κB p65 subunit activation in lymphocytes from RA, AS and PsA patients.